CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Innoviva - INVA CFD

-
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread -
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.024068 %
Charges from borrowed part ($-0.96)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.024068%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.001846 %
Charges from borrowed part ($0.07)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.001846%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* N/A
Open* N/A
1-Year Change* N/A
Day's Range* N/A
52 wk Range 10.64-20.71
Average Volume (10 days) 972.32K
Average Volume (3 months) 14.60M
Market Cap 773.23M
P/E Ratio 4.86
Shares Outstanding 68.13M
Revenue 331.34M
EPS 2.33
Dividend (Yield %) N/A
Beta 0.58
Next Earnings Date Apr 25, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low

Innoviva Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 331.339 391.866 336.794 261.016 261.004
Revenue 331.339 391.866 336.794 261.016 261.004
Total Operating Expense -121.69 16.763 15.671 14.656 22.753
Selling/General/Admin. Expenses, Total 63.538 16.187 13.883 14.656 22.753
Research & Development 41.432 0.576 1.788 0 0
Operating Income 453.029 375.103 321.123 246.36 238.251
Interest Income (Expense), Net Non-Operating -162.707 73.799 33.47 -13.12 -22.294
Other, Net -3.373 -3.626 -0.348 -0.345 -5.702
Net Income Before Taxes 286.949 445.276 354.245 232.895 210.255
Net Income After Taxes 220.262 368.837 293.814 190.993 406.328
Net Income Before Extra. Items 213.921 265.854 224.402 157.288 395.056
Total Extraordinary Items 0
Net Income 213.921 265.854 224.402 157.288 395.056
Income Available to Common Excl. Extra. Items 213.921 265.854 224.402 157.288 395.056
Income Available to Common Incl. Extra. Items 213.921 265.854 224.402 157.288 395.056
Diluted Net Income 216.36 270.59 229.119 157.288 395.056
Diluted Weighted Average Shares 95.248 94.31 113.554 113.409 113.408
Diluted EPS Excluding Extraordinary Items 2.27154 2.86915 2.01771 1.38691 3.48349
Diluted Normalized EPS 0.28877 2.86915 2.01771 1.38691 3.48349
Minority Interest -6.341 -102.983 -69.412 -33.705 -11.272
Dilution Adjustment 2.439 4.736 4.717
Cost of Revenue, Total 13.793
Gross Profit 317.546
Depreciation / Amortization 5.581
Unusual Expense (Income) -246.034
Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
Total revenue 65.803 67.257 108.22 90.059 107.68
Revenue 65.803 67.257 108.22 90.059 107.68
Total Operating Expense 41.622 -221.97 25.666 32.992 3.153
Selling/General/Admin. Expenses, Total 17.454 27.81 11.782 6.492 3.113
Research & Development 9.985 11.725 13.884 5.838 0.04
Operating Income 24.181 289.227 82.554 57.067 104.527
Interest Income (Expense), Net Non-Operating -86.246 -2.831 -61.531 -12.099 -46.448
Other, Net -2.623 0.028 -0.528 -0.25 -1.59
Net Income Before Taxes -64.688 286.424 20.495 44.718 56.489
Net Income After Taxes -68.314 229.347 21.371 37.858 45.65
Minority Interest 0 36.176 -20.432 -22.085 -35.305
Net Income Before Extra. Items -68.314 265.523 0.939 15.773 10.345
Net Income -68.314 265.523 0.939 15.773 10.345
Income Available to Common Excl. Extra. Items -68.314 265.523 0.939 15.773 10.345
Income Available to Common Incl. Extra. Items -68.314 265.523 0.939 15.773 10.345
Dilution Adjustment 3.175 3.654 2.569 1.183
Diluted Net Income -68.314 268.698 4.593 18.342 11.528
Diluted Weighted Average Shares 95.776 95.83 95.653 93.73 81.632
Diluted EPS Excluding Extraordinary Items -0.71327 2.8039 0.04802 0.19569 0.14122
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS -0.71327 0.57547 0.04802 0.38231 0.14122
Unusual Expense (Income) 0 -266.696 0 20.662
Cost of Revenue, Total 10.113 3.68
Gross Profit 55.69 63.577
Depreciation / Amortization 4.07 1.511
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total Current Assets 313.673 342.058 431.234 199.043 200.369
Cash and Short Term Investments 201.525 246.487 350.845 114.908 129.075
Cash & Equivalents 201.525 246.487 278.096 62.417 73.336
Short Term Investments 0 72.749 52.491 55.739
Total Receivables, Net 110.711 93.931 79.427 83.286 70.54
Accounts Receivable - Trade, Net 110.711 93.931 79.427 83.286 70.54
Prepaid Expenses 1.437 1.64 0.962 0.849 0.754
Total Assets 926.395 999.57 724.826 548.193 367.337
Property/Plant/Equipment, Total - Net 0.012 0.028 0.033 0.16 0.209
Intangibles, Net 111.43 125.253 139.076 152.899 166.722
Other Long Term Assets, Total 17.435 93.973 154.483 196.091 0.037
Total Current Liabilities 5.807 6.11 5.371 5.7 34.742
Accounts Payable 0.027 0.066 0.01 0.011 0.601
Accrued Expenses 5.78 6.044 5.361 5.689 9.141
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 25
Other Current Liabilities, Total 0
Total Liabilities 511.652 459.658 411.331 394.61 610.196
Total Long Term Debt 394.653 385.517 377.12 382.855 574.362
Long Term Debt 394.653 385.517 377.12 382.855 574.362
Other Liabilities, Total 0 0.106 0.219 0.586 0.94
Total Equity 414.743 539.912 313.495 153.583 -242.859
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.696 1.014 1.013 1.011 1.019
Additional Paid-In Capital 1264.02 1260.9 1258.86 1256.27 1258.15
Retained Earnings (Accumulated Deficit) -456.148 -722.002 -946.404 -1103.69 -1498.75
Treasury Stock - Common -393.829 0 -3.263
Other Equity, Total 0 0.027 -0.003 -0.018
Total Liabilities & Shareholders’ Equity 926.395 999.57 724.826 548.193 367.337
Total Common Shares Outstanding 69.5655 101.392 101.288 101.098 101.896
Minority Interest 111.192 67.925 28.621 5.469 0.152
Long Term Investments 483.845 438.258
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 317.823 313.673 236.928 148.261 372.933
Cash and Short Term Investments 216.802 201.525 135.115 43.265 282.89
Cash & Equivalents 216.802 201.525 135.115 43.265 282.89
Total Receivables, Net 93.515 110.711 101.271 104.262 88.974
Accounts Receivable - Trade, Net 93.515 110.711 101.271 104.262 88.974
Prepaid Expenses 5.576 1.437 0.542 0.734 1.069
Total Assets 1107.47 926.395 887.239 789.15 1088.29
Property/Plant/Equipment, Total - Net 3.985 0.012 0.015 0.019 0.024
Intangibles, Net 212.974 111.43 114.885 118.341 121.797
Long Term Investments 544.437 483.845 507.116 473.677 519.325
Other Long Term Assets, Total 22.711 17.435 28.295 48.852 74.211
Total Current Liabilities 109.227 5.807 3.125 5.371 3.804
Accounts Payable 1.808 0.027 0.089 0.03 0.014
Accrued Expenses 11.403 5.78 3.036 5.341 3.79
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 720.832 511.652 484.428 459.37 453.829
Total Long Term Debt 442.731 394.653 392.295 389.989 387.728
Long Term Debt 442.731 394.653 392.295 389.989 387.728
Minority Interest 165.575 111.192 88.994 63.965 62.22
Other Liabilities, Total 3.299 0 0.014 0.045 0.077
Total Equity 386.642 414.743 402.811 329.78 634.461
Common Stock 0.696 0.696 0.695 0.695 1.014
Additional Paid-In Capital 1182.91 1264.02 1262.44 1261.84 1261.33
Retained Earnings (Accumulated Deficit) -403.137 -456.148 -466.493 -538.931 -627.879
Total Liabilities & Shareholders’ Equity 1107.47 926.395 887.239 789.15 1088.29
Total Common Shares Outstanding 69.594 69.5655 69.492 69.495 101.408
Preferred Stock - Non Redeemable, Net 0 0 0 0
Treasury Stock - Common -393.829 -393.829 -393.829 -393.829
Other Current Assets, Total 1.93
Goodwill, Net 5.544
Current Port. of LT Debt/Capital Leases 96.016
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Net income/Starting Line 368.837 293.814 190.993 406.328 134.272
Cash From Operating Activities 363.813 313.113 257.458 223.531 141.749
Cash From Operating Activities 13.832 13.84 13.874 13.872 13.982
Non-Cash Items -78.415 -40.639 7.621 16.145 21.775
Cash Interest Paid 9.933 9.933 10.974 17.861 40.353
Changes in Working Capital -16.873 -14.322 3.095 -16.76 -28.28
Cash From Investing Activities 43.722 -314.937 -18.003 3.519 -23.236
Capital Expenditures 0 -0.013 -0.012 0 0
Other Investing Cash Flow Items, Total 43.722 -314.924 -17.991 3.519 -23.236
Cash From Financing Activities -452.497 -29.785 -23.776 -237.969 -163.193
Financing Cash Flow Items -59.457 -30.129 -10.553 -5.955 0.023
Total Cash Dividends Paid 0 0 -0.011 -0.08 -0.281
Issuance (Retirement) of Stock, Net -393.04 0.344 0.538 -1.934 -99.193
Issuance (Retirement) of Debt, Net 0 0 -13.75 -230 -63.742
Net Change in Cash -44.962 -31.609 215.679 -10.919 -44.68
Deferred Taxes 76.432 60.42 41.875 -196.054
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line 37.858 368.837 323.187 220.541 109.695
Cash From Operating Activities 98.102 363.813 265.432 168.721 84.107
Cash From Operating Activities 3.501 13.832 10.376 6.918 3.46
Deferred Taxes 6.86 76.432 65.6 45.069 19.736
Non-Cash Items 31.684 -78.415 -124.495 -93.637 -52.003
Cash Interest Paid 5.411 9.933 9.933 4.967 4.967
Changes in Working Capital 18.199 -16.873 -9.236 -10.17 3.219
Cash From Investing Activities -143.156 43.722 63.627 63.627 -26.394
Capital Expenditures -0.009 0 0 0 0
Other Investing Cash Flow Items, Total -143.147 43.722 63.627 63.627 -26.394
Cash From Financing Activities 60.331 -452.497 -440.431 -435.57 -21.31
Financing Cash Flow Items -6.507 -59.457 -46.358 -41.446 -21.285
Issuance (Retirement) of Stock, Net 0.214 -393.04 -394.073 -394.124 -0.025
Net Change in Cash 15.277 -44.962 -111.372 -203.222 36.403
Total Cash Dividends Paid 0
Issuance (Retirement) of Debt, Net 66.624 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
BlackRock Institutional Trust Company, N.A. Investment Advisor 14.3359 9766472 318524 2022-12-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 10.3365 7041846 54802 2022-12-31 LOW
Sarissa Capital Management, L.P. Hedge Fund 9.7085 6614000 0 2022-12-31 LOW
Putnam Investment Management, L.L.C. Investment Advisor/Hedge Fund 7.3406 5000852 49183 2022-12-31 LOW
Renaissance Technologies LLC Hedge Fund 6.2085 4229607 -36066 2022-12-31 HIGH
Westfield Capital Management Company, L.P. Investment Advisor/Hedge Fund 6.0273 4106136 145968 2022-12-31 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 4.7077 3207194 271075 2022-12-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 3.3086 2253988 -216906 2022-12-31 LOW
Millennium Management LLC Hedge Fund 3.1327 2134156 -369816 2022-12-31 HIGH
Systematic Financial Management, L.P. Investment Advisor 2.8675 1953525 114784 2022-12-31 LOW
Assenagon Asset Management S.A. Investment Advisor 2.5143 1712874 -190058 2022-12-31 HIGH
LSV Asset Management Investment Advisor 2.4093 1641361 -1120342 2022-12-31 LOW
Pacer Advisors, Inc. Investment Advisor 2.2585 1538654 63256 2022-12-31 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.7568 1196821 46886 2022-12-31 LOW
Citadel Advisors LLC Hedge Fund 1.4466 985539 147595 2022-12-31 HIGH
D. E. Shaw & Co., L.P. Hedge Fund 1.4372 979124 46803 2022-12-31 MED
American Century Investment Management, Inc. Investment Advisor/Hedge Fund 1.045 711936 164118 2022-12-31 LOW
BofA Global Research (US) Research Firm 0.9805 667991 -8277 2022-12-31 LOW
Goldman Sachs & Company, Inc. Research Firm 0.9348 636816 -350775 2022-12-31 MED
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.9296 633331 25245 2022-12-31 LOW

Start a global, multi-asset portfolio with an award-winning platform

Trade now Desktop

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Innoviva Company profile

About Innoviva Inc

Innoviva, Inc. is a company with a portfolio of royalties and other healthcare assets. Its royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including, RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI) and TRELEGY ELLIPTA (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and royalties from the sales of ANORO and ELLIPTA. RELVAR/BREO is a once-daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (ICS) and fluticasone furoate (FF). ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, VI. TRELEGY ELLIPTA a once-daily combination medicine consisting of an ICS, LAMA and LABA.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Innoviva Inc revenues increased 16% to $391.9M. Net income increased 18% to $265.9M. Revenues reflect Royalty revenue from a related party increase of 20% to $391.9M. Net income benefited from Changes in fair values of equity invest increase of 81% to $91M (income), Research and Development decrease of 68% to $576K (expense), Interest and dividend income increase of 21% to $1.8M (income).

Equity composition

Common Stock $.01 Par, 04/11, 200M auth., 74,693,843 issd. Insiders own 21.99%. IPO 10/04, 6.15M shares @ $16 per share by Merrill Lynch & Co. 07/10, Class A Common Stock $.01 Par, 30M auth., 9,401,499 issd. GlaxoSmithKline owns 100%.

Industry: Pharmaceuticals (NEC)

1350 Old Bayshore Highway
Suite 400
BURLINGAME
CALIFORNIA 94010
US

Income Statement

  • Annual
  • Quarterly

People also watch

BTC/USD

27,177.45 Price
-2.340% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 66.00

XRP/USD

0.48 Price
+7.690% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.00480

Gold

1,956.69 Price
-1.120% 1D Chg, %
Long position overnight fee -0.0180%
Short position overnight fee 0.0097%
Overnight fee time 21:00 (UTC)
Spread 0.30

US100

12,694.70 Price
-0.810% 1D Chg, %
Long position overnight fee -0.0241%
Short position overnight fee 0.0018%
Overnight fee time 21:00 (UTC)
Spread 3.0

Still looking for a broker you can trust?

Join the 500.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading